Found: 16
Select item for more details and to access through your institution.
Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.
- Published in:
- 2009
- By:
- Publication type:
- journal article
New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer.
- Published in:
- Current Oncology Reports, 2016, v. 18, n. 3, p. 1, doi. 10.1007/s11912-016-0504-2
- By:
- Publication type:
- Article
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.
- Published in:
- Neuroendocrinology, 2018, v. 107, n. 1, p. 24, doi. 10.1159/000487237
- By:
- Publication type:
- Article
Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study.
- Published in:
- Cancers, 2022, v. 14, n. 18, p. N.PAG, doi. 10.3390/cancers14184509
- By:
- Publication type:
- Article
Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterasesensitive cross-linker in patients with advanced malignancies: a Phase I study.
- Published in:
- International Journal of Nanomedicine, 2016, v. 11, p. 6207, doi. 10.2147/IJN.S110274
- By:
- Publication type:
- Article
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 268, doi. 10.1159/000522418
- By:
- Publication type:
- Article
Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential.
- Published in:
- Therapeutic Advances in Medical Oncology, 2012, v. 4, n. 1, p. 9, doi. 10.1177/1758834011428147
- By:
- Publication type:
- Article
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
- Published in:
- 2017
- By:
- Publication type:
- journal article
Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
- Published in:
- Acta Oncologica, 2016, v. 55, n. 9/10, p. 1168, doi. 10.1080/0284186X.2016.1191670
- By:
- Publication type:
- Article
Targeting neuroendocrine tumor: mixing standard options with novel therapies.
- Published in:
- 2012
- By:
- Publication type:
- Editorial
Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 2, p. 127, doi. 10.1007/s11523-012-0216-y
- By:
- Publication type:
- Article
Sunitinib in pancreatic neuroendocrine tumors.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 2, p. 117, doi. 10.1007/s11523-012-0220-2
- By:
- Publication type:
- Article
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Rationale for targeted therapies in hepatocellular carcinoma.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 2, p. 81, doi. 10.1007/s11523-008-0079-4
- By:
- Publication type:
- Article
Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 20, p. 4981, doi. 10.1002/cncr.27520
- By:
- Publication type:
- Article
Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib.
- Published in:
- Oncologist, 2014, v. 19, n. 4, p. 394, doi. 10.1634/theoncologist.2013-0114
- By:
- Publication type:
- Article